Evidence-based use of the new diagnostic tools for TB-infection
|
|
- Ashlynn Horn
- 6 years ago
- Views:
Transcription
1 Evidence-based use of the new diagnostic tools for TB-infection Roland Diel, MD, MPH German Central Committee against Tuberculosis, Germany 20. Tuberkulose-Symposium in Münchenwiler, 24 th March
2 Why new diagnostic tools (IGRAs) for TB infection? Different cut offs for TST positivity in different countries (e.g. contact tracing: USA 5mm, Germany >5mm, Switzerland >10mm) TST >15 mm do not necessarily represent latent TB infection (Tissot et al. 2005) Increased probability of false-positives in BCG-vaccinated or in NTM-infected persons (inconstant specificity) Increased risk of false-negative results due to application failures and in immunocompromised people Booster phenomenon in serial testing (e.g. of healthcare workers) Better compliance to chemoprevention than with the TST achievable? 2
3 Background for IGRA research Experts remain divided over the replacement of TST by IGRAs Current evidence about accuracy of IGRAs and the TST must be assessed Sensitivity (for diagnosis of active TB as surrogate for sensitivity of LTBI) Specificity Influence of exposure gradients on test results Negative and positive predictive values for progression Assessment should be focussed on the newest commercial IGRAs (QFT-IT, T-Spot.TB) 3
4 Definitions Specificity calculations ability of a test to give a negative result if a person is not infected healthy subjects with no known TB risk in low-burden countries required Negative Predictive Value for progression Proportion of IGRA/TST score-negative persons that do not progress to active TB in a longitudinal, follow-up study Positive Predictive Value for progression Proportion of IGRA/TST score-positive persons that develop active TB in a longitudinal, follow-up study 4
5 Sensitivity of IGRAs and TST as a surrogate parameter for latent TB in Pai s meta-analysis Pai M, Zwerling A, Menzies D. Systematic Review: T-Cell-based assays for the diagnosis of latent tuberculosis infection: An update. Ann Int Med 2008; 149:
6 New meta-analysis only on commercial IGRAs 6
7 Studies included in the meta-analysis Commercial formats of QFT-In Tube or T-Spot.TB test only Excludes Liquid antigen QFT-Gold (2G) and pre-commercial ELISpot Studies with original data only For T-Spot.TB, used 6 spot cut-off (European, not the FDA-approved criteria) Studies excluded where mitogen control not used Sensitivity calculations - positive culture, PCR, or histology required Excluded if treated for more than 2 weeks PPD interpreted using cut-off employed in the respective papers 7
8 Sensitivity of TST in Diel et al. 25 Studies (10 studies more than in Pai) 8
9 Sensitivity of QFT-IT in Diel et al. 16 Studies 9
10 Sensitivity of T-Spot.TB in Diel et al. 17 Studies 10
11 Sensitivity of TST and QFT-IT in blood Sester et al. ERJ 2010 TST 12 Studies QFT-IT 8 Studies 11
12 Sensitivity of T-Spot.TB in blood/extrasanguinously Sester et al. ERJ 2010 Blood 15 Studies Extrasanginous samples 7 Studies 12
13 Are IGRAs suitable for diagnosis of active TB? IGRAs are not rule out tests for active TB They lack the required sensitivity A positive IGRA is not proof of TB disease provides no information as to the source of an observed pathology low specificity for active TB (no differentiation between latent and active TB) designed for LTBI detection Can be used to aid diagnosis in special cases (unclear conclusions from other tools, suspected extrapulmonary TB, acutely symptomatic children) 13
14 New technology for active TB testing PCR-based molecular test Xpert MTB/RIF (Cepheid) outperforms IGRAS in diagnosis of active TB identifies 98.2% of all culture-confirmed TB cases and 72.5% of AFB-negative patients specific in 99.2% of controls 14
15 Specificity for LTBI diagnosis in individuals with low risk for LTBI Study Country Type of participants No. subjects No. subjects scored negative/ all tested* No. subjects considered false positive Specificity of IGRA(s) Specificity of TST Detjen 2007 Germany (Low burden) Children with confirmed non TB lymphadenitis or respiratory infections 45 T SPOT: 39/40 QFT: 40/40 TST: 22/40 T SPOT: 1 QFT: 0 TST: 18 (all 18 with NTM lymphadenitis) T SPOT: 98% QFT: 100% 55% Franken 2007 Netherlands (Low burden) Dutch Armed Forces personnel 171 QFT: 166/168 TST: 136/145 QFT:2 TST: 9 QFT: 99% 94% Palazzo 2008 Italy (Low burden) Healthy blood donors as controls for TB suspects 24 QFT: 14/14 TST: N.A. QFT: 0 QFT: 100% N.A. Ruhwald 2008 Denmark (Low burden) 86 high school students and 38 high school staff 124 QFT:124/124 TST: 116/124 QFT: 0 TST: 8 (10mm cutoff) QFT: 100% 95% Wang 2010 USA (low burden) 97 adult university volunteers and 11 hospital children 108 T Spot ( European cutoff):105/108 T Spot : 3 T Spot: 97% N.A. *after subtraction of invalid results/indeterminates N.A.: not assessed Pooled specificity QFT: 99.4% [95% CI %] Pooled specificity TST: 88.7% [95% CI %] Specificity T Spot: 97.2% 97.5% 15
16 Interpretation of a TST-result given 72% sensitivity, 89% specificity and 20% LTBI prevalence 1000 contacts tested 200 with LTBI 800 without LTBI 144 TP 56 FN 712 TN 88 FP Probability of LTBI in a contact with a positive TST result (PPV): 144/232 = 62.1% Probability of no LTBI in a contact with a negative TST result (NPV): 712/768 = 92.7% 16
17 Interpretation of an IGRA-result given 85% sensitivity, 99% specificity and 20% LTBI prevalence 1000 contacts tested 200 with LTBI 800 without LTBI 170 TP 30 FN 792 TN 8 FP Probability of LTBI in a contact with a positive IGRA result (PPV): 170/178 = 95.5% Probability of no LTBI in a contact with a negative IGRA result (NPV): 792/822 = 96.4% 17
18 Exposure and test positivity indirect approach to specificity Study Country No. and type of participants No. BCG vaccinees No. IGRA positives/ total tested IGRA (Odds Ratio) No. TST positives/ total tested TST (Odds Ratio) Bartalesi 2009 Casas 2009 Italy 398 IMID subjects Spain 147 HCWs 15.6% 4.1% 13.1% QFT: % 6.5 T SPOT: 38.8% QFT: 29.3% T SPOT: 2.1 QFT: n.s. 70.1% n.s* Hesseling 2009 South Africa 82 close contacts (29 children and 53 adults) 75.6% T Spot: 74.1% T SPOT: QFT: 39.2% QFT: % 3.83 Laffitte 2009 Lien 2009 Matulis 2008 Switzerland 50 anti TNFalpha treatment candidates 92.8% 20% T Spot: 5.67 (Contact history) T-Spot: 25.3 (Lesions in CXR) 40.0% n.s. Vietnam 300 HCWs > one third 47.3% QFT: % not calculated Switzerland 142 rheumatic patients 83.1% 12.0% QFT: 17.8 (Contact history) QFT: 66.8 (Lesions in CXR) 40.0% 6.23 *n.s.: not significant 18
19 Exposure and test positivity (continued) Study Country No. and type of participants Seyhan 2010 Turkey 100 hemodialysis patients No. BCG vaccinees 72.0% 43% No. IGRA positives/ total tested IGRA (Odds Ratio) QFT: 5.08 (Contact history) QFT: 3.06 (Lesions in CXR) No. TST positives/ total tested TST (Odds Ratio) 34.0% not calculated Triverio 2009 Switzerland 62 ERDS patients 22.6% T SPOT: 29.0% T SPOT: 1.2 QFT: 21.0% QFT: % n.s. Vinton 2009 Australia 481 hospital staff members 78.0% 8.4% QFT: % n.s. Zellweger 2005 Switzerland 91 contact persons 85.7% 16.5% T Spot: % n.s. *n.s.: not significant 19
20 IGRAs and PPV for progression IGRAs do detect more accurately those subjects who are truly infected Much more specific, sensitive (proven in active TB patients) Stronger correlation with risk factors for LTBI But : Do the IGRAs single out those most likely to progress to active TB after an exposure? Do they have a higher predictive value for progression than does the TST? 20
21 Theoretical considerations Comparing TST and IGRA testing with respect to PPV for infection, simple analysis of sensitivity and specificity estimates tells us that: IGRAs should be more accurate and higher than the TST at predicting who develops TB! TST IGRA But what do the data published to date tell us? denotes no. of false-positive, uninfected contacts 21
22 Positive predictive value for progression Diel et al. ERJ 2010 / Leung et al. AJRCCM 2010 Study Number and type of participants Country Performance of IGRA(s)/TST testing Follow up period (months) No. later TB cases among untreated IGRA positives No. later TB cases among untreated TST positives Clark immunodeficient HIV 1 +ve adults UK (Low burden) N.A.* 24 T Spot: 10% Not assessed Diel close contacts of AFB +ve TB cases Germany (Low burden) Simultaneously with TST 24 (mean) QFT: 14.6% TST >5mm: 2.3% Aichelburg HIV 1 +ve adults Austria (Low burden) IGRA first, TST only if QFT +ve 19 (mean) QFT: 8.3% Not assessed Kik adult close immigrant and BCG vaccinated Dutchborn contacts The Netherlands (Low burden) TST first, IGRAs only if TST +ve 22 (median) QFT: 2.8% T SPOT: 3.3% TST 10mm: 3.1% Leung male adult silicosis patients (most patients BCG unvaccinated) Hong Kong (Intermediat eburden) Simultaneously with TST 30 (mean) T SPOT: 4.5% TST 10mm: 1,64% (difference TST + / TSTnot significant 22
23 Selection bias in progression studies No. of contacts developing TB during the study period (nominator) Contacts at risk initially included (intended denominator) Contacts at the end of the study period (definite denominator) time Progression rate (nominator/denominator) depends on assessment of drop outs! 23
24 Predictive value of QFT-IT Diel et al. AJRCCM close contacts 79 without TST, 3 indeterminate 381 moved 954 close contacts 198 QFT positive 606 TST positive 759 QFT negative 348 TST negative 147 refused INH/RIF 51 with INH/RIF 555 without INH/RIF Follow up: % Person-years 0% 3.1% 0% 0.6% 19 developed active TB 0 developed active TB 17 developed active TB 0 active TB 2 active TB 24
25 A recent study on progression to active TB An analysis of 2,204 tuberculosis contacts using QuantiFERON TB Gold In-Tube and PPD P Haldar, H Thuraisingham, W Hoskyns, G Woltmann University Hospitals of Leicester, UK Abstract presented: British Thoracic Society,
26 Screening TB contacts in Leicester, UK Haldar et al. Thorax ,204 close contacts 1039 QFT Gold In-Tube 1165 no QFT 204 QFT positive 835 QFT negative* Approx # 110 no (or unfinished) chemoprevention Approx # 90 with chemoprevention No chemoprevention 17.2% Follow up: 445 days average 4.7% 1.6% 19 developed active TB 1 developed active TB No active TB cases 19 active TB * Indeterminates not reported # Approximate estimates only, as actual number are not reported 26
27 Results of progression studies IGRAs predict progression with high variability - at least in low and intermediate incidence countries There are only very few studies unconditionally comparing TST and IGRAs Progression rates also depend on individual or social risks - risk levels are probably different between natives (or naturalised subjects) and recent immigrants A universal progression rate can simply not be determined; studies different in design and done on different subjects/groups will have different outcomes 27
28 Rate of progression to TB for contacts scored positive Diel et al. AJRCCM 2010 QFT No. untreated contacts Progressed to active TB Progression rate Positive % Negative % TST (mm) # 2 0.6% > % > % > % p < p < 0.01 p < 0.05 * for the untreated 903 subjects who had QFT and TST results and remained in Hamburg. 28
29 Implications for preventive therapy Diel et al. AJRCCM 2010 Number of people needed to treat to stop 1 case of active TB: QFT = 8 With all cases detected = 33 With ~10% of cases missed = 21 With ~50% of cases missed Higher accuracy makes identification and treatment of LTBI: More effective Less expensive - as fewer people require treatment Practical 29
30 Multiple logistic regression analysis for progression to TB Diel et al. AJRCCM 2010 Progression to TB Odds ratio 95% CI Interval p IFN- level (IU/mL)* < TST induration diameter (mm) (n.s.) Age (yrs) < 0.02 Gender (n.s.) Origin outside Germany (n.s.) BCG vaccination (n.s.) Cumulative exposure time (hrs) (n.s.) * for the untreated 903 subjects who had QFT and TST results and remained in Hamburg. 30
31 Negative predictive value of IGRAs Diel et al. ERJ 2010 Study, Year Clark et al Diel et al Aichelburg et al Kik et al Lee et al (Infection) Silverman et al No. study members 47 UK (Low burden) 601 Germany (Low burden) 830 Austria (Low burden) 327 Netherlands (Low burden) 32 Taiwan (Intermediate burden) 23 Canada (Low burden) Country Type Duration of follow up (mo.) HIV- 1 positive individuals Close contacts of smear positive TB cases HIV-1 positive adults Close immigrant contacts of smear positive TB cases ERDS patients and healthy controls Visitors of BCG vacc. bladder cancer patients IGRA (s) used Mean age (yrs S D) 24 T-Spot median 40 (range: 33 46) 24 (mean) QFT 27.7 ( 12.0) 19 (mean) QFT 39 (range: 32 47) 22 (median) T-Spot/ QFT 24 T-Spot QFT No. TB cases developed in testnegative subjects No. false negative cases NPV (%, CI 95%) a % [ ] % [ ] % [ ] N.A. T-Spot/QFT:5 T-Spot: 2; QFT: 3 T-Spot: 98.3% [ ]; QFT: 98.0% [ ] % [ ] % [ ] 31
32 NPV for progression of QFT-IT and T-Spot.TB Pooled values - Diel et al. ERJ 2010 NPV (95% CI) Patients n/n Aichelburg et al ( ) 738/738 Diel et al ( ) 535/535 Kik et al ( ) 146/149 Silvermann et al ( ) 20/ Pooled NPV (QFT-G-IT) = (0.994 to 1.0) Chi-square = 13.67; df = 3 (p = ) Inconsistency (I-square) = 78.1 % Negative predictive value for progression NPV (95% CI) Patients n/n Clark et al ( ) 47/47 Kik et al ( ) 116/118 Lee et al ( ) 15/ Pooled NPV (T-Spot.TB) = 0.98 (0.94 to 0.99) Chi-square = 5.86; df = 2 (p = ) Inconsistency (I-square) = 65.9 % Negative predictive value for progression 32
33 How do IGRAs perform in children? 33
34 IGRA testing in children: Factors for consideration Young children are at increased risk of progressing to TB if infected TB often takes appears in very serious forms in children Very young children may not be immunocompetent Evidence has been collected for decades on the use of TST in children Poor specificity in those BCG-vaccinated and carrying NTM infections To date, only limited data on sensitivity of IGRAs (for detecting active TB) in children, not only in those <5 years! 34
35 IGRA and TST sensitivity in detecting active TB in children Study Country; IGRA used Mean Age (range) Bamford et al Bianchi et al Connell et al Cruz et al Detjen et al Kampmann et al Nichol et al TST -Sensitivity n/n (%) GB; QFT/T-Spot 10.1 (0.6-16) yrs 37/45 (82.2) Italy; QFT Australia; QFT/T-Spot USA; T-Spot Germany; QFT/T-Spot 54.0 ( ) months 8.2 ( ) yrs 7/9 (77.8) IGRA-Sensitivity n/n (%) QFT: 36/46 (78.3) T-Spot: 18/27 (66.7) 14/16 (87.5) 15/16 (93.8) QFT:8/9 (88.9) T-Spot: 9/9 (100.0) 8.6 (0.1-18) yrs 10/13 (76.9) 12/13 (92.3) 28 (4-85) months 28/28 (100.0) GB; QFT/T-Spot 9,2 (0.5-15) yrs 20/25 (80.0) South Africa; T-Spot Median 18 months, (interquartil range months) Pooled Sensitivity: TST: 124/146; 84.9% [95% CI 78.1%-90.3%] QFT: 105/124; 84.6% [95% CI 77.1%-90.5%] T-Spot: 84/112; 75.0% [95% CI 65.9%-82.7%] QFT and T-Spot: 26/28 (92.9) QFT: 20/25 (80.0) T-Spot: 14/25 (56.0) 8/10 (80.0) 5/10 (50.0) 35
36 Diel et al. AJRCCM 2010: Data from children 104 close contact children Mean age 10.4 ± 4.3 years 36% BCG vaccinated 6 progressed to active TB 6/21 QFT positive (29%) developed TB None of the 83 QFT negative children developed TB 6/40 (15%) TST developed TB 2 of the 6 would have been missed by IGRA detects those likely to progress to active TB 36
37 A recent review of published literature: The Use of Interferon-gamma Release Assays in HIV positive Individuals Matthias Hoffmann and Pernille Ravn European Infectious Diseases 2010;4:
38 38
39 Rate of indeterminate IGRA results stratified by CD4+ count in HIV-positive individuals without active tuberculosis Indeterminate responses correlate with CD4+ count 39
40 IGRAs in HIV positives Superior sensitivity in HIV positive compared to TST But lower than in HIV negative Patients with CD4 >200 cells/ L have performance comparable to HIV negative More indeterminates than in HIV-negatives Indeterminate responses associated with low CD4 cell count Not a rule out - test (up to 35% false negative for active TB) - But better than the TST 40
41 Iatrogenic immunosuppression (especially anti-tnf-α therapy) 41
42 Comparison of QFT and TST in RA patients in Peru Ponce De Leon et al. J Rheumatol 2008 Objectives: Compare TST and QFT positivity in RA patients with matched controls Determine the level of agreement between these tests Determine the performance of both tests by age groups Methods: 101 outpatients with Rheumatoid Arthritis 93 immunocompetent controls Matched by age, gender Osteoporosis, osteoarthritis, mechanic lumbar pain and tendinitis Positive TST 5mm for RA patients and 10 mm for Controls QFT-IT performed as per manufacturer s instructions 42
43 Responses in controls vs RA patients Ponce De Leon et al. J Rheumatol 2008 Highly significant drop in TST sensitivity for RA patients Less effect for IGRA 43
44 LTBI testing and IGRAs-Conclusions With IGRAs, what has changed in the way we look at TB? IGRAs are more specific and more sensitive (in adults) than PPD What does this mean in practical terms? IGRAs allow the exclusion of M. tuberculosis infection with higher reliability In longitudinal studies in low prevalence countries NPV for progression was high for both IGRAs IGRA positivity is clearly associated with exposure to infectious TB cases Odd ratios of IGRA positivity usually exceeds those for the TST 44
45 LTBI testing and IGRAs-Conclusions. IGRAs are likely more predictive of future TB This should change our attitudes to screening and treating LTBI But: More larger-sized and better designed studies needed to evaluate Sensitivity of IGRAs in Children Predictive values of IGRAs in immune-deficient hosts and children 45
Evaluation and Treatment of TB Contacts Tyler, Texas April 11, 2014
Evaluation and Treatment of TB Contacts Tyler, Texas April 11, 2014 Interferon Gamma Release Assays: Understanding the Test David Griffith, BA, MD April 11, 2014 David Griffith, BA, MD has the following
More informationTB Prevention Who and How to Screen
TB Prevention Who and How to Screen 4.8.07. IUATLD 1st Asia Pacific Region Conference 2007 Dr Cynthia Chee Dept of Respiratory Medicine / TB Control Unit Tan Tock Seng Hospital, Singapore Cycle of Infection
More informationAT HIGH RISK OF PROGRESSING TO ACTIVE TB? Senior Lecturer and Consultant Physician University Hospitals of Leicester UK
HOW WELL DO IGRAS PERFORM IN THE IDENTIFICATION OF PERSONS WHO ARE AT HIGH RISK OF PROGRESSING TO ACTIVE TB? Dr Pranab Haldar MD MRCP Senior Lecturer and Consultant Physician University Hospitals of Leicester
More informationTB Intensive Houston, Texas October 15-17, 2013
TB Intensive Houston, Texas October 15-17, 2013 Interferon Gamma Release Assays (IGRA s) Lisa Armitige, MD, PhD October 16, 2013 Lisa Armitige, MD, PhD has the following disclosures to make: No conflict
More informationUpdate on IGRA Predictive Value
Update on IGRA Predictive Value Sandra Kik, PhD Molebogeng Rangaka, MD, PhD Madhukar Pai, MD, PhD McGill International TB Centre, McGill University University of Cape Town & London School of Hygiene and
More informationPredictive Value of interferon-gamma release assays for incident active TB disease: A systematic review
Predictive Value of interferon-gamma release assays for incident active TB disease: A systematic review Lele Rangaka University of Cape Town, South Africa mxrangaka@yahoo.co.uk 1 The 3 I s Isoniazid preventive
More informationApproaches to LTBI Diagnosis
Approaches to LTBI Diagnosis Focus on LTBI October 8 th, 2018 Michelle Haas, M.D. Associate Director Denver Metro Tuberculosis Program Denver Public Health DISCLOSURES I have no disclosures or conflicts
More informationTB Intensive San Antonio, Texas November 11 14, 2014
TB Intensive San Antonio, Texas November 11 14, 2014 Interferon Gamma Release Assays Lisa Armitige, MD, PhD November 12, 2014 Lisa Armitige, MD, PhD has the following disclosures to make: No conflict of
More informationMycobacterial Infections: What the Primary Provider Should Know about Tuberculosis
Mycobacterial Infections: What the Primary Provider Should Know about Tuberculosis Henry F. Chambers, M.D Professor of Medicine, UCSF Topics for Discussion Epidemiology Diagnosis of active TB Screening
More informationCategory Description / Key Findings Publication
PUBLICATIONS Selected T-SPOT.TB test publications, by area of interest, up to 31 th August 2016. Category Description / Key Findings Publication Background A useful primer on the evolution, administration
More informationPeggy Leslie-Smith, RN
Peggy Leslie-Smith, RN EMPLOYEE HEALTH DIRECTOR - AVERA TRAINING CONTENT 1. South Dakota Regulations 2. Iowa Regulations 3. Minnesota Regulations 4. Interferon Gamma Release Assay (IGRA)Testing 1 SOUTH
More informationRichard O Brien, Consultant, FIND 3 rd Global Symposium on IGRAs Waikoloa, Hawaii, 13 January 2012
Global l Applications of IGRAs Richard O Brien, Consultant, FIND 3 rd Global Symposium on IGRAs Waikoloa, Hawaii, 13 January 2012 Disclosure I have no personal financial conflicts of I have no personal
More informationDiagnosis Latent Tuberculosis. Disclosures. Case
Diagnosis Latent Tuberculosis Neha Shah MD MPH Field Medical Officer Tuberculosis Control Branch California Department of Public Health Centers for Disease Control and Prevention September 2016 1 Disclosures
More informationInterpretation of TST & IGRA results. Objectives
Interpretation of TST & IGRA results Randall Reves, MD, MSc Volunteer Clinician Denver Metro TB Program and Division of Infectious Diseases, Department of Medicine University of Colorado Denver Objectives
More informationTesting for TB. Bart Van Berckelaer Territory Manager Benelux. Subtitle
Testing for TB Bart Van Berckelaer Territory Manager Benelux Subtitle Agenda TB infection pathway TB immunisation Testing options Pre lab considerations of the whole blood ELISA test The T-SPOT.TB test
More informationTargeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection (LTBI) Lloyd Friedman, M.D. Milford Hospital Yale University
Targeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection (LTBI) Lloyd Friedman, M.D. Milford Hospital Yale University Tuberculosis Estimates USA World Infection 15,000,000 2,000,000,000
More informationUsing Interferon Gamma Release Assays for Diagnosis of TB Infection
Learning Objectives Using Interferon Gamma Release Assays for Diagnosis of TB Infection 1. Describe available Interferon Gamma Release Assay tests for TB infection and how they work. 2. Understand interpretation
More informationTB Intensive Tyler, Texas December 2-4, 2008
TB Intensive Tyler, Texas December 2-4, 2008 Interferon Gamma Releasing Assays: Diagnosing TB in the 21 st Century Peter Barnes, MD December 2, 2008 TOPICS Use of interferon-gamma release assays (IGRAs)
More informationDetecting latent tuberculosis using interferon gamma release assays (IGRA)
Detecting latent tuberculosis using interferon gamma release assays (IGRA) American Society for Microbiology June 2017 Edward Desmond, Ph.D., D (ABMM) San Lorenzo, CA Edward Desmond has no financial connections
More informationInterferon Gamma Release Assay Testing for Latent Tuberculosis Infection: Physician Guidelines
Interferon Gamma Release Assay Testing for Latent Tuberculosis Infection: Physician Guidelines Historically, Latent Tuberculosis Infection (LTBI) diagnosis was based on risk assessment, chest x-ray (CXR)
More informationTargeted Testing and the Diagnosis of. Latent Tuberculosis. Infection and Tuberculosis Disease
Self-Study Study Modules on Tuberculosis Targeted Testing and the Diagnosis of Latent Tuberculosis Infection and Tuberculosis Disease 1 Module 3: Objectives At completion of this module, learners will
More informationWhat the Primary Physician Should Know about Tuberculosis. Topics for Discussion. Global Impact of TB
What the Primary Physician Should Know about Tuberculosis Henry F. Chambers, M.D Professor of Medicine, UCSF Topics for Discussion Epidemiology Common disease presentations Diagnosis of active TB Screening
More informationBarbara J Seaworth MD Medical Director, Heartland National TB Center Professor, Internal Medicine and Infectious Disease UT Health Northeast
Practical Aspects for Using the Interferon Gamma Release Assay (IGRA) Test Live Webinar July 14, 2017 Barbara J Seaworth MD Medical Director, Heartland National TB Center Professor, Internal Medicine and
More informationWhat the Primary Physician Should Know about Tuberculosis. Topics for Discussion. Life Cycle of M. tuberculosis
What the Primary Physician Should Know about Tuberculosis Henry F. Chambers, M.D Professor of Medicine, UCSF Topics for Discussion Microbiology Epidemiology Common disease presentations Diagnosis of active
More informationLatent Tuberculosis Infections Controversies in Diagnosis and Management Update 2016
Latent Tuberculosis Infections Controversies in Diagnosis and Management Update 2016 Randy Culpepper, MD, MPH Deputy Heath Officer/Medical Director Frederick County Health Department March 16, 2016 2 No
More informationTuberculin Skin Test (TST) and Interferon-gamma Release Assays (IGRA)
Tuberculin Skin Test (TST) and Interferon-gamma Release Assays (IGRA) April 2019 Bob Belknap M.D. Director, Denver Metro TB Program Disclosures No relevant financial relationships Objectives Be able to
More informationTB Nurse Case Management San Antonio, Texas July 18 20, 2012
TB Nurse Case Management San Antonio, Texas July 18 20, 2012 IGRA s and Their Use in TB Nurse NCM Lisa Armitige, MD, PhD July 18, 2012 Lisa Armitige, MD, PhD has the following disclosures to make: No conflict
More information결핵노출접촉자감염관리 서울아산병원감염내과 김성한
결핵노출접촉자감염관리 서울아산병원감염내과 김성한 TB incidence (2012) TB incidence South Korea 108 China 73 Taiwan 68 Portucal 26 Japan 19 Spain 14 US 3.6 * unit- per 100,000 population Adapted from WHO Adapted from WHO Emerg
More informationIGRAs for Diagnosis of Tuberculosis: 2010 Update
IGRAs for Diagnosis of Tuberculosis: 2010 Update Nira Pollock, M.D., Ph.D. Division of Infectious Diseases Beth Israel Deaconess Medical Center Boston, MA May 1, 2010 Problems with the PPD False positives
More informationReport on WHO Policy Statements
Report on WHO Policy Statements Christopher Gilpin TB Diagnostics and Laboratory Strengthening Unit Secretariat, Global Laboratory Initiative Stop TB Department, WHO Geneva New Diagnostics Working Group
More informationThorax Online First, published on December 8, 2009 as /thx
Thorax Online First, published on December 8, 2009 as 10.1136/thx.2009.119677 Title Page Cost effectiveness of the NICE guidelines for screening for latent tuberculosis infection: the Quantiferon-TB gold
More informationConflict of Interest Disclosures:
Mady Slater, M.D. Stanford University Medical Center Division of Infectious Diseases 04/23/14 WOEMA webinar Conflict of Interest Disclosures: I have no financial relationships with commercial entities
More informationJeffrey R. Starke, M.D. has the following disclosures to make:
AAP 2018 Red Book Tuberculosis: IGRAs and Treatment of TB Infection Jeffrey R. Starke, M.D. May 31, 2018 AAP 2018 Red Book Childhood Tuberculosis: IGRAs and Treatment of TB Infection May 31, 2018 WEBINAR
More informationTuberculin Skin Test (TST) and Interferon-gamma Release Assays (IGRA)
Tuberculin Skin Test (TST) and Interferon-gamma Release Assays (IGRA) April 2018 Bob Belknap M.D. Director, Denver Metro TB Program No Disclosures Objectives be able to describe: 1. Who should get tested
More informationLTBI-Tuberculin skin test. T-Spot.TB Technology. QuantiFERON -TB Gold In Tube T-SPOT.TB ELISA ELISA
LTBI-Tuberculin skin test QuantiFERON -TB Gold In Tube ELISA PPD ~200 antigens 3 ml blood ESAT-6 TB 7.7 16-24 hour incubation Nil Negative control PHA Positive control Andersen et al Lancet 2000;356:1099-1104
More informationDiagnostic challenges of active childhood TB in Tanzania. Michala Vaaben Rose, MD, Ph.D Department of Infectious Diseases, Hvidovre
Diagnostic challenges of active childhood TB in Tanzania Michala Vaaben Rose, MD, Ph.D Department of Infectious Diseases, Hvidovre 1 Diagnosis of Childhood Tuberculosis Muheza hospital, TZ Hilleroedhospital.dk
More informationScreening for Tuberculosis Infection. Harlingen, TX. Linda Dooley, MD has the following disclosures to make:
TB Infection Diagnosis Recommendations Talk Developed by Lisa Y. Armitige, MD, PhD Medical Consultant, Heartland National TB Center Associate Professor Internal Medicine/Pediatrics/Infectious Disease UT
More informationNguyen Van Hung (NTP, Viet Nam)
Technical Consultation Meeting on the Programmatic Management of Latent Tuberculosis Infection 31 August-1 September 2017, Seoul, Republic Korea Adopting new LTBI diagnostics at country level: perspective
More informationContracts Carla Chee, MHS May 8, 2012
Moving Past the Basics of Tuberculosis Phoenix, Arizona May 8-10, 2012 Contracts Carla Chee, MHS May 8, 2012 Carla Chee, MHS has the following disclosures to make: No conflict of interests No relevant
More informationDiagnosis of tuberculosis
Diagnosis of tuberculosis Madhukar Pai, MD, PhD Assistant Professor, Epidemiology McGill University, Montreal, Canada madhukar.pai@mcgill.ca Global TB Case Detection A major concern 2.6 million new smear
More informationValidity of interferon-c-release assays for the diagnosis of latent tuberculosis in haemodialysis patients
ORIGINAL ARTICLE BACTERIOLOGY Validity of interferon-c-release assays for the diagnosis of latent tuberculosis in haemodialysis patients W. K. Chung 1,2, Z. L. Zheng 1, J. Y. Sung 1, S. Kim 1,H.H.Lee 1,
More informationLet s Talk TB A Series on Tuberculosis, A Disease That Affects Over 2 Million Indians Every Year
A Series on Tuberculosis, A Disease That Affects Over 2 Million Indians Every Year Madhukar Pai, MD, PhD Author and Series Editor Camilla Rodrigues, MD co-author Abstract Most individuals who get exposed
More information(2) 83.3% b/w TST and T-SPOT, (2) 77.4% b/w TST and T-SPOT. 77.7% b/w TST and QFT-GIT. QFT-GIT, 22.2% in T-SPOT. TSPOT vs. TST (> 5 mm) vs.
Supplementary Table 1. Study characteristics of the included literature Low to moderate TB endemic region Shovman et al. (2009) [21] Minguez et al. (2012) [16], type 35 RA 35 RA 53 Patients with s (RA
More information2016 OPAM Mid-Year Educational Conference, Sponsored by AOCOPM Sunday, March 13, 2016
Learning Objectives Tuberculosis Case Discussions: Evaluation for Tuberculosis Infection Melissa C. Overman, DO, MPH, CHES, FAOCOPM Describe appropriate technique for TST placement, reading and interpretation
More informationDimitrios Vassilopoulos,* Stamatoula Tsikrika, Chrisoula Hatzara, Varvara Podia, Anna Kandili, Nikolaos Stamoulis, and Emilia Hadziyannis
CLINICAL AND VACCINE IMMUNOLOGY, Dec. 2011, p. 2102 2108 Vol. 18, No. 12 1556-6811/11/$12.00 doi:10.1128/cvi.05299-11 Copyright 2011, American Society for Microbiology. All Rights Reserved. Comparison
More informationEvidence on IGRAs in Low & Middle Income Countries. Madhukar Pai, MD, PhD McGill University, Montreal
Evidence on IGRAs in Low & Middle Income Countries Madhukar Pai, MD, PhD McGill University, Montreal Madhukar.pai@mcgill.ca Disclosure No industry/financial conflicts I co-chair the Stop TB Partnership
More informationUse of an Interferon- Release Assay To Diagnose Latent Tuberculosis Infection in Foreign-Born Patients*
Original Research MYCOBACTERIAL DISEASE Use of an Interferon- Release Assay To Diagnose Latent Tuberculosis Infection in Foreign-Born Patients* Daniel Brodie, MD; David J. Lederer, MD, MS; Jade S. Gallardo,
More informationDidactic Series. Latent TB Infection in HIV Infection
Didactic Series Latent TB Infection in HIV Infection Jacqueline Peterson Tulsky, MD UCSF Positive Health Program at SFGH Medical Director, SF and North Coast AETC March 13, 2014 ACCREDITATION STATEMENT:
More informationPathogenesis of Rheumatoid Arthritis. Smolen, J. S. et al. (2012) Nat. Rev. Rheumatol. doi: /nrrheum
1 Pathogenesis of Rheumatoid Arthritis 2 Smolen, J. S. et al. (2012) Nat. Rev. Rheumatol. doi:10.1038/nrrheum 2012.23 Biologic therapies used in the treatment of rheumatoid arthritis 3 Etanercept Infliximab
More informationLaboratory Updates on IGRA Testing
Laboratory Updates on IGRA Testing Edward A. Graviss, PhD, MPH, FIDSA August 18, 2017 EXCELLENCE EXPERTISE INNOVATION Edward A. Graviss, PhD, MPH, FIDSA, has the following disclosures to make: No conflict
More informationThe Most Widely Misunderstood Test of All
The Most Widely Misunderstood Test of All Lee B. Reichman, MD, MPH NJMS Global Tuberculosis Institute History of Treatment of Latent Tuberculosis Infection For more than 4 decades, treatment of persons
More informationSelf-Study Modules on Tuberculosis
Self-Study Modules on Tuberculosis Targe te d Te s ting and the Diagnosis of Latent Tuberculosis Infection and Tuberculosis Disease U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control
More informationMaking the Diagnosis of Tuberculosis
Making the Diagnosis of Tuberculosis Alfred Lardizabal, MD NJMS Global Tuberculosis Institute Testing for TB Infection Targeted Testing: Key Points Test only if plan for ensuring treatment De-emphasizes
More information10/3/2017. Updates in Tuberculosis. Global Tuberculosis, WHO 2015 report. Objectives. Disclosures. I have nothing to disclose
Disclosures Updates in Tuberculosis I have nothing to disclose Chris Keh, MD Assistant Clinical Professor, Division of Infectious Diseases, UCSF TB Controller, TB Prevention and Control Program, Population
More informationNew Standards for an Old Disease:
New Standards for an Old Disease: Practical Implications of the TB Standards TB Prevention and Control Saskatchewan September 16, 2015 Practical Implications of the TB Standards Learning Objectives At
More informationTuberculosis Tools: A Clinical Update
Tuberculosis Tools: A Clinical Update CAPA Conference 2014 JoAnn Deasy, PA-C. MPH, DFAAPA jadeasy@sbcglobal.net Adjunct Faculty Touro PA Program Learning Objectives Outline the pathogenesis of active pulmonary
More informationDiagnosis and Medical Case Management of Latent TB. Bryan Rock, MD April 27, 2010
TB Nurse Case Management Lisle, Illinois April 27-28, 28 2010 Diagnosis and Medical Case Management of Latent TB Infection Bryan Rock, MD April 27, 2010 DIAGNOSIS AND MANAGEMENT OF LATENT TUBERCULOSIS
More informationLTBI: Who to Test & When to Treat
LTBI: Who to Test & When to Treat TB Intensive May 10 th, 2016 David Horne, MD, MPH Harborview Medical Center University of Washington DISCLOSURES I have no disclosures or conflicts of interest to report
More informationEl futuro del diagnostico de la ITL. en tiempos de crisis. Professor Ajit Lalvani FMedSci Chair of Infectious Diseases
El futuro del diagnostico de la ITL. en tiempos de crisis Taller de TB de Barcelona, Noviembre 2012 Professor Ajit Lalvani FMedSci Chair of Infectious Diseases Department of Respiratory Medicine National
More informationTitle: Role of Interferon-gamma Release Assays in the Diagnosis of Pulmonary Tuberculosis in Patients with Advanced HIV infection
Author's response to reviews Title: Role of Interferon-gamma Release Assays in the Diagnosis of Pulmonary Tuberculosis in Patients with Advanced HIV infection Authors: Adithya Cattamanchi (acattamanchi@medsfgh.ucsf.edu)
More informationCHILDHOOD TUBERCULOSIS: NEW WRINKLES IN AN OLD DISEASE [FOR THE NON-TB EXPERT]
CHILDHOOD TUBERCULOSIS: NEW WRINKLES IN AN OLD DISEASE [FOR THE NON-TB EXPERT] QUESTION: : Which children in the United States should get a tuberculin skin test? Do questionnaires really work? Jeffrey
More informationLatent Tuberculosis Best Practices
Latent Tuberculosis Best Practices Last Updated September 7, 2016 LTBI Demographics in the US o 13million people in the US with LTBI (estimate) o In 2014, approximately 66% of TB cases in the United States
More informationPreventing Tuberculosis (TB) Transmission in Ambulatory Surgery Centers. Heidi Behm, RN, MPH TB Controller HIV/STD/TB Program
Preventing Tuberculosis (TB) Transmission in Ambulatory Surgery Centers Heidi Behm, RN, MPH TB Controller HIV/STD/TB Program Topics of Discussion TB Overview Epidemiology of TB in Oregon Annual Facility
More informationPredictive values of IGRAs and TST for progression to active disease in TB. 3 rd Global IGRA Symposium January 2012.
Predictive values of IGRAs and for progression to active disease in TB contacts in Singapore Cynthia B E Chee 1, K W KhinMar 1, S H Gan 1, J Cutter, T M Barkham, Y T Wang 1 1 TB Control Unit, Tan Tock
More informationTuberculosis Intensive
Tuberculosis Intensive San Antonio, Texas April 3 6, 2012 Childhood Tuberculosis Kim Smith, MD, MPH April 6, 2012 Kim Smith, MD, MPH has the following disclosures to make: No conflict of interests No relevant
More informationEffect of prolonged incubation time on the results of the QuantiFERON TB Gold In-Tube assay for the diagnosis of latent tuberculosis infection
CVI Accepts, published online ahead of print on 3 July 2013 Clin. Vaccine Immunol. doi:10.1128/cvi.00290-13 Copyright 2013, American Society for Microbiology. All Rights Reserved. 1 2 3 Effect of prolonged
More informationEvidence-Based Comparison of Commercial Interferon- g Release Assays for Detecting Active TB
CHEST Special Feature Evidence-Based Comparison of Commercial Interferon- g Release Assays for Detecting Active TB A Metaanalysis Roland Diel, MD, MPH ; Robert Loddenkemper, MD, FCCP ; and Albert Nienhaus,
More informationAuthor's response to reviews
Author's response to reviews Title: Contribution of Interferon Gamma Release Assays testing to the Diagnosis of Latent Tuberculosis Infection in HIV-Infected Patients: A comparison of QuantiFERON Gold
More informationTuberculosis: Where Are We Now?
Tuberculosis: Where Are We Now? Amee Patrawalla MD MPH Rutgers - NJ Medical School Global TB Institute Rutgers, The State University of New Jersey Learning Objectives Understand the current epidemiologic
More informationUnderstanding and Managing Latent TB Infection Arnold, Missouri October 5, 2010
Understanding and Managing Latent TB Infection Arnold, Missouri October 5, 2010 What is Latent TB Infection (LTBI)? Traci Hadley, RN October 5, 2010 LTBI or TB Disease? Presented by : Traci Hadley, RN
More informationTB in Corrections Phoenix, Arizona
TB in Corrections Phoenix, Arizona March 24, 2011 Treatment of Latent TB Infection Renuka Khurana MD, MPH March 24, 2011 Renuka Khurana, MD, MPH has the following disclosures to make: No conflict of interests
More informationTB Update: March 2012
TB Update: March 2012 David Schlossberg, MD, FACP Medical Director, TB Control Program Philadelphia Department of Public Health 1 TB Update: March 2012 IGRAs vs TST LTBI A New Regimen NAATs What is Their
More informationVariation in T-SPOT.TB spot interpretation between independent observers of different laboratories
8 Variation in T-SPOT.TB spot interpretation between independent observers of different laboratories Willeke P.J. Franken 1, Steven Thijsen 2, Ron Wolterbeek 3, John J.M. Bouwman 2, Hanane el Bannoudi
More informationInvestigation of false-positive results by the QuantiFERON-TB Gold In-Tube assay
JCM Accepts, published online ahead of print on 11 July 2012 J. Clin. Microbiol. doi:10.1128/jcm.00730-12 Copyright 2012, American Society for Microbiology. All Rights Reserved. 1 2 Investigation of false-positive
More informationTuberculosis and TNF Inhibitors
Tuberculosis and TNF Inhibitors Sundari Mase MD, MPH Medical Team Lead CDC/DTBE/FSEB January 18, 2011 Objectives Discuss the association between and epidemiology of TNF inhibitors and TB Discuss the challenges
More informationUse of Interferon-γ Release Assays (IGRAs) in TB control in low and middle-income settings - EXPERT GROUP MEETING -
Use of Interferon-γ Release Assays (IGRAs) in TB control in low and middle-income settings - EXPERT GROUP MEETING - Date and time: 20-21 July 2010, 09:00 18:00 Venue: Salle B, WHO-HQ, Geneva, Switzerland
More informationESCMID Online Lecture Library. by author
Tuberculosis prevention in immunodepressed patients M. Carmen Fariñas Álvarez Infectious Diseases.H.U.Marqués de Valdecilla University of Cantabria, Spain DISCLOSURES I have no potential conflicts with
More informationL. Masae Kawamura, M.D. Senior Director, Medical and Scientific Affairs, Tuberculosis Clinician, San Francisco TB Clinic DISCLAIMER
IGRA update QuantiFERON -TB Gold Plus (QFT-Plus) L. Masae Kawamura, M.D. Senior Director, Medical and Scientific Affairs, Tuberculosis Clinician, San Francisco TB Clinic October, 2018 DISCLAIMER I am employed
More informationATS/CDC Guidelines for Treating Latent TB Infection
TB Intensive Tyler, Texas June 2-4, 2010 ATS/CDC Guidelines for Treating Latent TB Infection Timothy R. Aksamit, MD June 2, 2010 ATS/CDC Guidelines for Treating LTBI Tuberculosis Intensive University of
More informationIdentifying TB co-infection : new approaches?
Identifying TB co-infection : new approaches? Charoen Chuchottaworn MD. Senior Medical Advisor, Central Chest Institute of Thailand, Department of Medical Services, MoPH Primary tuberculosis Natural history
More informationLatent Tuberculosis in Adults: From Testing TO Treatment
Latent Tuberculosis in Adults: From Testing TO Treatment Sergio M. Borgia, MD, MSc., FRCP(C) Infectious Diseases Consultant, WOHS Medical Director, WOHS Tuberculosis Clinic Assistant Clinical Professor,
More informationTuberculosis Update. Topics to be Addressed
Tuberculosis Update Robert M. Jasmer, M.D. University of California, San Francisco TB Control Section, San Francisco Department of Public Health Topics to be Addressed TB in the USA Screening recommendations
More informationClinical Policy Title: Interferon-gamma release assays for tuberculosis screening
Clinical Policy Title: Interferon-gamma release assays for tuberculosis screening Clinical Policy Number: 07.01.06 Effective Date: March 1, 2014 Initial Review Date: November 20, 2013 Most Recent Review
More informationUtility of PPD or IGRA to answer the age old question of "TB or not TB
Utility of PPD or IGRA to answer the age old question of "TB or not TB Thomas S. Alexander, Ph.D., D(ABMLI) Immunologist Summa Health alexandt@summahealth.org Yes, The reservation is in the name of Dr.
More informationLatent TB Infection (LTBI)
Latent TB Infection (LTBI) Diagnosis & Treatment of Latent TB Infection (LTBI) Amee Patrawalla MD MPH Assistant Professor UMDNJ-New Jersey Medical School Infection with Mycobacterium tuberculosis without
More informationTUBERCULOSIS. Pathogenesis and Transmission
TUBERCULOSIS Pathogenesis and Transmission TUBERCULOSIS Pathogenesis and Transmission Infection to Disease Diagnostic & Isolation Updates Treatment Updates Pathogenesis Droplet nuclei of 5µm or less are
More informationCommunity pharmacy-based tuberculosis skin testing
Community pharmacy-based tuberculosis skin testing Shanna K. O Connor, PharmD ISU KDHS Spring CE Seminar 2018 In support of improving patient care, Idaho State University Kasiska Division of Health Sciences
More informationJournal of Infectious Diseases Advance Access published August 2, 2013
Journal of Infectious Diseases Advance Access published August 2, 2013 1 Reversion and Conversion of Interferon-gamma Release Assay Results in HIV-1 Infected Individuals Maximilian C. Aichelburg 1,*, Thomas
More informationNew Approaches to the Diagnosis and Management of Tuberculosis Infection in Children and Adolescents
New Approaches to the Diagnosis and Management of Tuberculosis Infection in Children and Adolescents Jeffrey R. Starke, M.D. Professor of Pediatrics Baylor College of Medicine [With great thanks to Andrea
More informationCritical Evaluation of Tuberculosis Diagnostic Tests in Low- and High- Burden Settings
Critical Evaluation of Tuberculosis Diagnostic Tests in Low- and High- Burden Settings by John Metcalfe Dissertation submitted in partial satisfaction of the requirements for the degree of Doctor of Philosophy
More informationThe Challenges and Pitfalls in Diagnosing or Misdiagnosing Tuberculosis: Are the Days of TB Skin Tests Over?
The Challenges and Pitfalls in Diagnosing or Misdiagnosing Tuberculosis: Are the Days of TB Skin Tests Over? ROY F. CHEMALY, MD, MPH, FIDSA, FACP PROFESSOR OF MEDICINE DIRECTOR, INFECTION CONTROL SECTION
More informationInterferon-gamma release assay for treatment monitoring of active tuberculosis
JCM Accepts, published online ahead of print on 21 November 2012 J. Clin. Microbiol. doi:10.1128/jcm.02278-12 Copyright 2012, American Society for Microbiology. All Rights Reserved. 1 2 Interferon-gamma
More informationTB: Management in an era of multiple drug resistance. Bob Belknap M.D. Denver Public Health November 2012
TB: Management in an era of multiple drug resistance Bob Belknap M.D. Denver Public Health November 2012 Objectives: 1. Explain the steps for diagnosing latent and active TB role of interferon-gamma release
More informationWhat Is New in Combination TB Prevention? Lisa J. Nelson Treatment and Care (TAC) Team HIV Department WHO HQ
What Is New in Combination TB Prevention? Lisa J. Nelson Treatment and Care (TAC) Team HIV Department WHO HQ Outline Combination prevention for HIV Approaches to TB prevention Individual Household/key
More informationLiterature Overview. Health Economics. Experience with QuantiFERON -TB Gold. Cellestis Clinical Guide series
Literature Overview Experience with QuantiFERON -TB Gold Health Economics Cellestis Clinical Guide series 2008 www.cellestis.com This literature overview is intended to provide healthcare professionals
More informationTB Intensive San Antonio, Texas
TB Intensive San Antonio, Texas August 2, 2011 ATS/CDC Guidelines for Treating LTBI Timothy Aksamit, MD April 6, 2011 Timothy Aksamit, MD has the following disclosures to make: No conflict of interests
More informationDENOMINATOR: All patients aged 18 and older with a diagnosis of inflammatory bowel disease
Measure #274: Inflammatory Bowel Disease (IBD): Testing for Latent Tuberculosis (TB) Before Initiating Anti-TNF (Tumor Necrosis Factor) Therapy National Quality Strategy Domain: Effective Clinical Care
More informationReview. Interferon- assays in the immunodiagnosis of tuberculosis: a systematic review. Interferon- assays for tuberculosis diagnosis
Interferon- assays for tuberculosis diagnosis Review Interferon- assays in the immunodiagnosis of tuberculosis: a systematic review Madhukar Pai, Lee W Riley, and John M Colford Jr A major challenge in
More informationT-CELL RESPONSES ASSESSED USING IGRA AND TST ARE NOT CORRELATED WITH AFB GRADE AND CHEST RADIOGRAPH IN PULMONARY TUBERCULOSIS PATIENTS
T-CELL RESPONSES ASSESSED USING IGRA AND TST ARE NOT CORRELATED WITH AFB GRADE AND CHEST RADIOGRAPH IN PULMONARY TUBERCULOSIS PATIENTS Kiatichai Faksri 1, 4, Wipa Reechaipichitkul 2, 4, Wilailuk Pimrin
More information